ABSTRACT: 
Patients with advanced cancers were enrolled in protocols based on direct intratumoral injection of immature Dendritic cells (iDC).  To augment antigen uptake and antitumor immune response, iDC injection was combined with radiotherapy and injection of Activated T cells (AT).  Clinical responses were evaluated by Response Evaluation Criteria in Solid Tumors (RECIST), and the majority of patients showed partial regression (PR) or stable disease (SD).  Several patients achieved complete response at injected and metastatic sites.  Treatments were well tolerated with no adverse reactions.  The clinical responses observed in cancer patients with advanced disease suggest potential effectiveness of combination strategies of intratumoral injection of iDC, radiotherapy and AT, and they establish the basis for the current treatment protocol.  Taking advantage of the ability of Dendritic Cells to acquire antigenic materials from their environment and generate primary as well as recall immune responses, we conclude that the combining conventional therapies with intratumoral injection of autologous Dendritic Cells and Activated T cells would be the potent way to treat patients with advanced cancers.

PROFILE:  Dr. Kenichiro Hasumi, M.D., is a physician specialized in cancer immunotherapy and terminal care.  He is also a researcher and visionary focused on the development of cancer vaccines and improved clinical treatments to achieve better patient outcomes with a higher quality of life.  In 1999, Dr. Hasumi established the Hasumi International Research Foundation (HIRF) in the United States.  The primary purpose of HIRF is to conduct and support scientific research in connection with finding a cure for various forms of cancer, particularly with the use of immunotherapy.  Its mission is to develop a highly sophisticated database and networking system for the collection and dissemination of valuable data from cancer research and treatment throughout the world.  Currently, with his ever-growing vision to help cancer patients, Dr. Hasumi as the HIRF's Chairman, has been supporting various cancer researches in the United States, Japan, Taiwan and China. HIRF has also been sponsoring the International Cancer Vaccine Symposium since 2001.  Dr. Hasumi is also chairman of Shukokai Clinic, Hijirigaoka Hospital, Hijiri-no-Sato Elderly Health Care Facility, The Electro-Chemical and Cancer Institute, and ICVS Tokyo Clinic & Research Institute; all these institutions are located in Tokyo, Japan.  He was the primary organizer and founder for the World Immuno-Society for Health (WISH), a nonprofit organization helping physicians, patients and their families become more aware and understanding of cancer treatment and care through networking. He also holds a Singapore patent with the advanced cancer and immunotherapy which was granted in 2009.